Circulating miRNA29 family expression levels in patients with essential hypertension as potential markers for left ventricular hypertrophy

References

• Kearney PM, Whelton M, Reynolds K, Muntner P, et al. Global burden of hypertension: analysis of worldwide data. Lancet 2005;365:217–23.
   PubMed Web of Science ®Google Scholar
• Shimamoto K, Ando K, Fujita T, et al. The Japanese society of hypertension guidelines for the management of hypertension (JSH 2014). Hypertens Res 2014;37:253–390.
   PubMed Web of Science ®Google Scholar
• Lawes CM, Vander HS, Rodgers A. Global burden of blood-pressure-related disease, 2001. Lancet 2008;371:1513–8.
   PubMed Web of Science ®Google Scholar
• Pusuroglu H, Cakmak HA, Erturk M, et al. Assessment of the relation between mean platelet volume, non-dipping blood pressure pattern, and left ventricular mass index in sustained hypertension. Med Sci Monitor 2014;20:2020–6.
   PubMed Web of Science ®Google Scholar
• Ogihara T, Kikuchi K, Matsuoka H, et al. The Japanese society of hypertension guidelines for the management of hypertension (JSH 2009). Hypertens Res 2009;32:3–107.
   PubMed Web of Science ®Google Scholar
• Levy D, Garrison RJ, Savage DD, et al. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. New Engl J Med 1990;322:1561–6.
   PubMed Web of Science ®Google Scholar
• Devereux RB, Reichek N. Echocardiographic determination of left ventricular mass in man. Anatomic validation of the method. Circulation 1977;55:613–8.
   PubMed Web of Science ®Google Scholar
• Schuster A, Ishida M, Morton G, et al. Value of cardiovascular magnetic resonance imaging in myocardial hypertrophy. Clin Res Cardiol 2012;101:237–8.
   PubMed Web of Science ®Google Scholar
• Kitagawa K, Choi BW, Chan C, et al. ASCI 2010 appropriateness criteria for cardiac magnetic resonance imaging: a report of the Asian Society of Cardiovascular Imaging cardiac computed tomography and cardiac magnetic resonance imaging guideline working group. Int J Cardiovas Imag 2010;26:173–86.
   PubMed Web of Science ®Google Scholar
• Sinitsyn VE, Iurpol’Skaia LA, Stukalova OV, et al. The problem of the accurate noninvasive diagnosis of left ventricular myocardial hypertrophy in essential hypertension: the role of magnetic resonance tomography. Terapevt Arkh 1997;69:13–5.
   PubMed Web of Science ®Google Scholar
• Heggermont WA, Heymans S. MicroRNAs are involved in end-organ damage during hypertension. Hypertension 2012;60:1088–93.
   PubMed Web of Science ®Google Scholar
• Yang Z, Chen H, Si H, et al. Serum miR-23a, a potential biomarker for diagnosis of pre-diabetes and type 2 diabetes. Acta Diabetol 2014;51:823–31.
   PubMed Web of Science ®Google Scholar
• Cengiz M, Karatas OF, Koparir E, et al. Differential expression of hypertension-associated microRNAs in the plasma of patients with white coat hypertension. Medicine (Baltimore) 2015;94:e693.
   PubMed Web of Science ®Google Scholar
• Li S, Zhu J, Zhang W, et al. Signature microRNA expression profile of essential hypertension and its novel link to human cytomegalovirus infection. Circulation 2011;124:175–84.
   PubMed Web of Science ®Google Scholar
• van Rooij E, Sutherland LB, Thatcher JE, et al. Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis. P Natl Acad Sci USA 2008;105:13027–32.
   PubMed Web of Science ®Google Scholar
• Hill JA, Karimi M, Kutschke W, et al. Cardiac hypertrophy is not a required compensatory response to short-term pressure overload. Circulation 2000;101:2863–9.
   PubMed Web of Science ®Google Scholar
• Molkentin JD, Lu JR, Antos CL, et al. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell 1998;93:215–28.
   PubMed Web of Science ®Google Scholar
• van Rooij E, Sutherland LB, Liu N, et al. A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure. P Natl Acad Sci USA 2006;103:18255–60.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Huang XR, Wei LH, et al. miR-29b as a therapeutic agent for angiotensin II-induced cardiac fibrosis by targeting TGF-beta/Smad3 signaling. Mol Ther 2014;22:974–85.
   PubMed Web of Science ®Google Scholar
• Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007;25:1105–87.
   Web of Science ®Google Scholar
• Taylor J. 2013 ESH/ESC guidelines for the management of arterial hypertension. Eur Heart J 2013;34:2108–9.
   Google Scholar
• Lang RM, Bierig M, Devereux RB, et al. Recommendations for chamber quantification. Eur J Echocardiogr 2006;7:79–108.
   PubMed Web of Science ®Google Scholar
• Kang K, Zhang X, Liu H, et al. A novel real-time PCR assay of microRNAs using S-Poly(T), a specific oligo(dT) reverse transcription primer with excellent sensitivity and specificity. PLoS One 2012;7:e48536.
   PubMed Web of Science ®Google Scholar
• Kuhlmann JD, Baraniskin A, Hahn SA, et al. Circulating U2 small nuclear RNA fragments as a novel diagnostic tool for patients with epithelial ovarian cancer. Clin Chem 2014;60:206–13.
   PubMed Web of Science ®Google Scholar
• Baraniskin A, Nopel-Dunnebacke S, Ahrens M, et al. Circulating U2 small nuclear RNA fragments as a novel diagnostic biomarker for pancreatic and colorectal adenocarcinoma. Int J Cancer 2013;132:E48–57.
   PubMed Web of Science ®Google Scholar
• Mishra PK, Tyagi N, Kumar M, Tyagi SC. MicroRNAs as a therapeutic target for cardiovascular diseases. J Cell Mol Med 2009;13:778–89.
   PubMed Web of Science ®Google Scholar
• Abdellatif M. Differential expression of microRNAs in different disease states. Circ Res 2012;110:638–50.
   PubMed Web of Science ®Google Scholar
• Wang J, Xu R, Lin F, et al. MicroRNA: novel regulators involved in the remodeling and reverse remodeling of the heart. Cardiology 2009;113:81–8.
   PubMed Web of Science ®Google Scholar
• Kriegel AJ, Liu Y, Fang Y, et al. The miR-29 family: genomics, cell biology, and relevance to renal and cardiovascular injury. Physiol Genomics 2012;44:237–44.
   PubMed Web of Science ®Google Scholar
• Ye Y, Perez-Polo JR, Qian J, Birnbaum Y. The role of microRNA in modulating myocardial ischemia-reperfusion injury. Physiol Genomics 2011;43:534–42.
   PubMed Web of Science ®Google Scholar
• Fort A, Borel C, Migliavacca E, Antonarakis SE, et al. Regulation of fibrinogen production by microRNAs. Blood 2010;116:2608–15.
   PubMed Web of Science ®Google Scholar
• Ye Y, Perez-Polo JR, Qian J, Birnbaum Y. The role of microRNA in modulating myocardial ischemia-reperfusion injury. Physiol Genomics 2011;43:534–42.
   PubMed Web of Science ®Google Scholar
• Qin J, Liang H, Shi D, et al. A panel of microRNAs as a new biomarkers for the detection of deep vein thrombosis. J Thromb Thrombolys 2015;39:215–21.
   PubMed Web of Science ®Google Scholar